-
公开(公告)号：KR1020150019330A
公开(公告)日：2015-02-25
申请号：KR1020130096071
申请日：2013-08-13
Applicant: 서울대학교산학협력단 , 연세대학교 산학협력단
Abstract: The present invention relates to a method for enhancing an immune reaction of immune cells including increase of an amount of active oxygen in immune cells in vitro. According to the present invention, growth of tumor can be inhibited and various immune diseases can be treated by improving the immune reaction of immune cells.
Abstract translation: 本发明涉及一种增强免疫细胞免疫反应的方法，包括在体外增加免疫细胞中活性氧的量。 根据本发明，可以抑制肿瘤的生长，通过改善免疫细胞的免疫反应来治疗各种免疫疾病。
-
公开(公告)号：KR101276180B1
公开(公告)日：2013-06-18
申请号：KR1020100108877
申请日：2010-11-03
Applicant: 서울대학교산학협력단 , 고려대학교 산학협력단
CPC classification number: C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/55555 , C07K7/06 , C07K14/001
Abstract: 본 발명은 산화아연-결합성 펩타이드를 포함하는 단백질과 산화아연 나노입자의 복합체, 의약의 제조를 위한 약물전달체로서의 그의 용도, 상기 복합체를 포함하는 백신 조성물 및 조영제를 제공한다. 산화아연-결합성 펩타이드를 포함하는 단백질은 산화아연 나노입자의 생체 내 활용성을 현저히 개선시키므로, 상기 복합체는 의약의 생체 내 또는 세포 내 전달을 위한 약물전달체로서 사용할 수 있을 뿐만 아니라 생체 또는 세포의 이미징을 위해 사용할 수 있으며, 생물제재를 효과적으로 분리할 수 있는 분리제, 온열치료를 비롯한 치료제, MRI 조영제, 바이오센서에 응용 가능한 비드(bead)의 제조를 위한 용도를 추가로 제공한다.
Abstract translation: 本发明涉及包含氧化锌结合肽和氧化锌纳米颗粒的蛋白质与其作为用于制备药物的药物递送载体的用途以及包含该复合物的疫苗组合物和造影剂的复合物。 包含氧化锌结合肽的蛋白质显着地改善了氧化锌结合肽的体内可利用性，因此本发明的复合物不仅可以用作用于体内药物递送或细胞内药物递送的药物递送载体，而且 也用于体内成像或细胞成像。 该复合物可用于制备用于有效分离生物材料的分离剂，用于高热疗法的治疗剂等，用于MRI的造影剂和适用于生物传感器的珠粒。
-
公开(公告)号：KR1020110063154A
公开(公告)日：2011-06-10
申请号：KR1020090120104
申请日：2009-12-04
Applicant: 서울대학교산학협력단
IPC: C07K19/00 , C07K14/35 , C07K14/155 , A61K39/00
Abstract: PURPOSE: A fusion antigen and a method for manufacturing a mature dendritic cell vaccine for immunotherapy using the same are provided to improve efficiency. CONSTITUTION: A fusion antigen used in manufacturing dendritic cell vaccine for immunotherapy contains PTD-MUC1 fusion protein containing MUC1(mucin antigen 1) fused to protein transduction domain(PTD) or PTD-Ag85A fusion protein. The fusion antigen is PTD-MUC1-Ag85A or PTD-Ag85A-MUC1. A method for manufacturing the dendritic cell vaccine comprises: a step of preparing immature dendritic cells; and a step of culturing the cells with the fusion antigen for maturing the cells. A pharmaceutical composition for anticancer immunotherapy contains pharmaceutically effective amount of the dendritic cell vaccine and pharmaceutically acceptable carrier.
Abstract translation: 目的：提供融合抗原和使用其制备用于免疫治疗的成熟树突状细胞疫苗的方法以提高效率。 构成：用于制备用于免疫治疗的树突状细胞疫苗的融合抗原包含与蛋白转导结构域（PTD）或PTD-Ag85A融合蛋白融合的含有MUC1（粘蛋白抗原1）的PTD-MUC1融合蛋白。 融合抗原为PTD-MUC1-Ag85A或PTD-Ag85A-MUC1。 树突细胞疫苗的制造方法包括：制备未成熟树突状细胞的步骤; 以及用于使细胞成熟的融合抗原培养细胞的步骤。 用于抗癌免疫疗法的药物组合物含有药学有效量的树突状细胞疫苗和药学上可接受的载体。
-
公开(公告)号：KR1020110049724A
公开(公告)日：2011-05-12
申请号：KR1020100108877
申请日：2010-11-03
Applicant: 서울대학교산학협력단 , 고려대학교 산학협력단
CPC classification number: C07K7/08 , A61K38/00 , A61K39/0011 , A61K2039/55555 , C07K7/06 , C07K14/001 , C07K14/47 , A61K47/50 , C07K17/14
Abstract: PURPOSE: A composite of zinc oxide nanoparticles and proteins containing zinc oxide-binding peptides is provided to modify biocompatibility of zinc oxide nanoparticles. CONSTITUTION: A composite of proteins contains zinc oxide-binding peptides and zinc oxide nanoparticles. The zinc oxide-binding peptide has a structure of [(Arg-X_1-X_2-Arg)_m-linker]_n, [(Arg-X_1-X_2-Arg-Lys)_m-linker]_n. In the formula, X_1 is Pro, Ala, Thr, Gln, or Ile; X_2 is His, Ile, Asn, or Arg. The zinc oxide-binding peptide has an amino acid sequence selected from the sequence numbers 1-4.
Abstract translation: 目的：提供氧化锌纳米粒子和含有氧化锌结合肽的蛋白质复合物，以改善氧化锌纳米粒子的生物相容性。 构成：蛋白质复合物含有氧化锌结合肽和氧化锌纳米粒子。 氧化锌结合肽具有[（Arg-X_1-X_2-Arg）_m-接头] n，[（Arg-X_1-X_2-Arg-Lys）-m-接头]]的结构。 在该式中，X_1为Pro，Ala，Thr，Gln或Ile; X_2是His，Ile，Asn或Arg。 氧化锌结合肽具有选自序列号1-4的氨基酸序列。
-
公开(公告)号：KR102027817B1
公开(公告)日：2019-10-02
申请号：KR1020170149837
申请日：2017-11-10
Applicant: 서울대학교산학협력단
IPC: C07K14/195 , G01N33/535 , G01N33/569 , A61K39/02 , A61K39/39
-
Patent Agency Ranking
公开(公告)号：KR101648922B1
公开(公告)日：2016-08-18
申请号：KR1020150132145
申请日：2015-09-18
Applicant: 서울대학교산학협력단
IPC: C12Q1/68
CPC classification number: Y02A50/59
Abstract: 본발명은오리엔티아쯔쯔가무시균의혈청형의동정방법및 그키트를개시한다. 구체적으로오리엔티아쯔쯔가무시균()의 sca 유전자특히 scaD 유전자의패신저도메인영역의길이차이에의한혈청형(serotype)의효과적인동정방법및 키트를개시한다.
-
公开(公告)号：KR101419791B1
公开(公告)日：2014-07-17
申请号：KR1020130003528
申请日：2013-01-11
Applicant: 서울대학교산학협력단
IPC: G01N33/53 , G01N33/563 , G01N33/68
CPC classification number: Y02A50/59
Abstract: The present invention relates to a composition and a kit for detecting specific antibodies for Orientia tsutsugamushi. The composition and the kit for detecting the specific antibodies for Orientia tsutsugamushi of the present invention are for particularly detecting the specific antibodies for Orientia tsutsugamushi derived ScaA, ScaB or ScaE. The composition and the kit of the present invention can be used for identifying an infected person or a non-infected person by Orientia tsutsugamushi, especially for identifying whether a patient showing the same or similar symptoms to tsutsugamushi disease is an infected person or a non-infected person by Orientia tsutsugamushi.
Abstract translation: 本发明涉及用于检测东方恙虫的特异性抗体的组合物和试剂盒。 用于检测本发明恙虫东方特异性抗体的组合物和试剂盒用于特异性检测恙虫Ori藜衍生的ScaA，ScaB或ScaE的特异性抗体。 本发明的组合物和试剂盒可用于鉴定恙虫病东方感染者或非感染者，特别是用于鉴定恙虫病患者是否显示相同或相似症状的患者是感染者或非感染者， 被东方恙虫病感染的人。
-
公开(公告)号：KR1020110093427A
公开(公告)日：2011-08-18
申请号：KR1020100013470
申请日：2010-02-12
Applicant: 서울대학교산학협력단
IPC: C07K16/18 , C12N15/63 , A61K39/395 , A61P35/00
CPC classification number: C07K16/3092
Abstract: PURPOSE: A single domain antibody or nanoscale antibody or nanoMAb is provided to diagnose cancer tissue which expresses MUC1 and to be used as an anti-tumor target therapeutic agent. CONSTITUTION: A single domain antibody for MUC1 contains a heavy chain variable region having: CDR1 selected from the group consisting of amino acids of sequence numbers 24-30; CDR2 selected from the group consisting of amino acids of sequence numbers 31-37; or CDR3 selected from the group consisting of amino acid of sequence number 38-44. The single domain antibody additionally contains a functional molecule. The functional molecule is chemicals, peptides, polypeptides, nucleic acids, carbohydrate, lipid, or inorganic particles.
Abstract translation: 目的：提供单域抗体或纳米抗体或纳米抗体，以诊断表达MUC1的癌组织，并用作抗肿瘤靶标治疗剂。 构成：用于MUC1的单结构域抗体包含重链可变区，其具有：CDR1，其选自序列号24-30的氨基酸; CDR2选自序列号31-37的氨基酸; 或选自序列号38-44的氨基酸的CDR3。 单结构域抗体另外含有功能性分子。 功能分子是化学物质，肽，多肽，核酸，碳水化合物，脂质或无机颗粒。
-
19.发明公开
公开(公告)号：KR1020140091347A
公开(公告)日：2014-07-21
申请号：KR1020130003511
申请日：2013-01-11
Applicant: 서울대학교산학협력단
CPC classification number: Y02A50/59 , C12Q1/6844 , C12N15/11
Abstract: Disclosed are a method and a kit for identification of serotype of Orientia tsutsugamushi. Specifically, disclosed are a method and a kit for effective identification of serotype by length difference of a passenger domain region of sca genes, especially of scaD genes of Orientia tsutsugamushi.
Abstract translation: 公开了用于鉴定恙虫东方of血清型的方法和试剂盒。 具体地，公开了通过Sca基因，特别是恙虫东方sc D基因的乘客区域的长度差异有效地鉴定血清型的方法和试剂盒。
-
20.发明公开쯔쯔가무시 균 특이적 프로브 세트 및 이를 포함하는 마이크로어레이 有权具有特异性的东方TS US HI AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME AME
公开(公告)号：KR1020110100751A
公开(公告)日：2011-09-15
申请号：KR1020100019747
申请日：2010-03-05
Applicant: 서울대학교산학협력단
CPC classification number: Y02A50/59 , C12Q1/689 , C12Q1/6837
Abstract: 본 발명은 오리엔티아 쯔쯔가무시 균(
Orientia tsutsugamushi )에 특이적인 프로브 세트 및 이를 포함하는 마이크로어레이를 개시한다. 구체적으로 본 발명은 오리엔티아 쯔쯔가무시 균 게놈(GeneBank accession no. AM494475)에 기초하여 제작된 총 1611개의 프로브와 이들 프로브를 집적시킨 마이크로어레이를 개시한다.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.027 seconds)
